Table 4.
Meta-analysis results of primary outcomes.
| Indication | Type of intervention | Number of studies included | Cases | Heterogeneity test | Effect model | Results of the meta-analysis | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Experimental group | Control group | I 2 | p | OR (95% CI) | z | p | ||||
| Acute PID | Total effective rate | 23 | 0.0% | 0.999 | F | 5.57 (4.09, 7.58) | 10.90 | 0.001 | ||
| FKQJP + control group | Penicillin | 6 | 549 | 0.0% | 0.711 | F | 5.77 (3.17, 10.49) | 5.74 | 0.001 | |
| FKQJP + control group | Penicillin + metronidazole | 7 | 801 | 0.0% | 0.887 | F | 7.80 (4.00, 15.18) | 6.04 | 0.001 | |
| FKQJP + control group | Quinolones | 2 | 206 | 0.0% | 0.584 | F | 3.99 (1.81, 8.77) | 3.44 | 0.001 | |
| FKQJP + control group | Quinolones + nitroimidazole | 2 | 140 | 0.0% | 0.773 | F | 7.23 (1.78, 29.28) | 2.77 | 0.006 | |
| FKQJP + control group | Roxithromycin | 2 | 180 | 0.0% | 0.809 | F | 4.59 (1.63, 12.96) | 2.88 | 0.004 | |
| FKQJP + control group | Metronidazole | 2 | 132 | 0.0% | 0.330 | F | 2.96 (1.07, 8.22) | 2.08 | 0.037 | |
| FKQJP + moxifloxacin | Ceftriaxone + tinidazole | 2 | 220 | 0.0% | 0.829 | F | 5.90 (2.45, 14.20) | 3.96 | 0.001 | |
| Incidence of adverse reaction | 10 | 10 | 958 | 0.0% | 0.989 | F | 0.71 (0.45, 1.10) | 1.55 | 0.121 | |
| Chronic PID | Total effective rate | 69 | 8478 | 0.0% | 0.999 | F | 4.70 (4.07, 5.42) | 21.21 | 0.001 | |
| FKQJP | β-Lactam + nitroimidazole | 2 | 284 | 0.0% | 0.735 | F | 2.55 (1.52, 4.28) | 3.53 | 0.001 | |
| FKQJP + control group | β-Lactam | 7 | 626 | 0.0% | 0.939 | F | 3.88 (2.34, 6.45) | 5.24 | 0.001 | |
| FKQJP + control group | β-Lactam + nitroimidazole | 7 | 700 | 0.0% | 0.918 | F | 6.27 (3.46, 11.37) | 6.04 | 0.001 | |
| FKQJP+β-lactam + nitroimidazole | FKQJP | 2 | 250 | 0.0% | 0.579 | F | 7.80 (3.29, 18.50) | 4.66 | 0.001 | |
| FKQJP + control group | Macrolide | 15 | 1905 | 0.0% | 0.869 | F | 3.54 (2.67, 4.68) | 8.81 | 0.001 | |
| FKQJP + control group | Quinolone | 8 | 892 | 0.0% | 0.925 | F | 5.54 (3.61, 8.52) | 7.82 | 0.001 | |
| FKQJP + control group | Quinolone + nitroimidazole | 30 | 3821 | 0.0% | 1.000 | F | 5.67 (4.49, 7.16) | 14.56 | 0.001 | |
| Incidence of adverse reaction | 30 | 3082 | 0.0% | 0.708 | F | 0.60 (0.46, 0.80) | 3.55 | 0.001 | ||
| Endometritis | Total effective rate | 30 | 3521 | 0.0% | 0.998 | F | 5.09 (4.03, 6.43) | 13.63 | 0.001 | |
| FKQJP + control group | Antibiotics | 4 | 680 | 0.0% | 0.979 | F | 9.01 (4.23, 19.21) | 5.69 | 0.001 | |
| FKQJP + antibiotics | Antibiotics + progesterone | 12 | 1122 | 0.0% | 0.969 | F | 4.84 (3.25, 7.21) | 7.77 | 0.001 | |
| FKQJP + control group | Antibiotics + progesterone | 11 | 1279 | 0.0% | 0.959 | F | 4.40 (3.03, 6.39) | 7.78 | 0.001 | |
| FKQJP + control group | Antibiotics + progesterone + vaginal douche | 3 | 440 | 0.0% | 0.758 | F | 5.25 (2.92, 9.44) | 5.54 | 0.001 | |
FKQJP, Fuke Qianjin tablet; R, random-effect model; F, fix-effect model.